# Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle

> **NCT01071200** · PHASE3 · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 133 (actual)

## Conditions studied

- Reproductive Techniques, Assisted

## Interventions

- **DRUG:** Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)
- **DRUG:** r-hFSH

## Key facts

- **NCT ID:** NCT01071200
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-03
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2013-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01071200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01071200, "Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01071200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*